```json
{
"content": [
{
"type": "paragraph",
content": "The ELISA Test Kits market outlook is underpinned by a $2.9 B revenue base growing at ~7 % CAGR, propelled by chronic-disease surveillance, biopharma QC, and emerging-market screening programs. Competitive intensity is moderate-to-high: four multinationals control half of global supply, yet nimble specialty houses keep price pressure acute and force 12–18 month product refresh cycles. Over the next five years demand will outstrip supply by 5–7 %, especially for high-throughput allergen and autoimmune assays, creating margin expansion for vendors able to secure critical HRP and antibody inputs."
},
{
"type": "paragraph",
"content": "Long-term, the sector is structurally attractive—recurring reagent pull-through, limited generic erosion, and rising per-capita testing—but faces policy volatility (IVDR, CDC re-zoning) and bio-analytical substitution risk from multiplex and CRISPR diagnostics. Innovation is migrating toward AI-driven lot-to-lot calibration, room-temperature lyophilized beads, and SARS-CoV-2 / flu A+B combo panels; pioneers will capture >35 % of 2028 incremental profit pools. Investors should weigh raw-material concentration, shipping cold-chain exposure, and pricing scrutiny as the three dominant risk levers."
}
]
}
```
